The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The popular weight-loss and diabetes medication tirzepatide is no longer in short supply, the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.

Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...